IDH1 and acute myeloid leukemia: Of particular interest, 50% of IDH2mut and 83% of IDH1mut AML relapses occurring in IDH triplet treated patients have been IDH wildtype, suggesting effective eradication of the original IDHmut AML and evolution or progression of a separate clone.